Phase 2b clinical trial results for tyk2 inhibitor presented at american academy of dermatology annual meeting

Boston--(business wire)--results from the phase 2b clinical trial of tak-279 (formerly ndi-034858), a novel allosteric tyk2 inhibitor developed by nimbus therapeutics and owned by takeda (tse:4502/nyse:tak), in patients with moderate-to-severe plaque psoriasis were presented on saturday, march 18, 2023 at the 2023 american academy of dermatology (aad) annual meeting in new orleans. the results were presented as part of the late-breaking research session by april armstrong, m.d.
TAK Ratings Summary
TAK Quant Ranking